| Non-Hodgkin Lymphoma (NHL) |
1 |
1 |
| Skin Cancer |
0 |
0.99 |
| Lymphoma |
0 |
0.84 |
| Cutaneous Lymphoma |
0 |
0.79 |
| B-Cell Lymphoma |
0 |
0.74 |
| Cutaneous B-Cell Lymphoma |
0 |
0.73 |
| T-Lymphocyte |
0 |
0.21 |
| Bone Marrow |
0 |
0.15 |
| Bone |
0 |
0.14 |
| Plasma |
0 |
0.14 |
| Antineoplastic Drug |
0 |
0.07 |
| Biologic Therapy |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Intravenous |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Lymph Node |
0 |
0.07 |
| Monoclonal Antibody |
0 |
0.07 |
| Private Practice |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |
| Trunk |
0 |
0.07 |